The antiangiogenic and antineoplastic activities of the butyric acid prodrugs AN-7 and AN-9 were demonstrated in vitro with HUVEC by inhibition of proliferation and vascular tubes formation, enhanced apoptosis, and inhibition of 22Rv-1 cells migration. In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1α, HER-2/neu, bFGF and increased PTEN level. AN-7 and AN-9 reduced hemoglobin accumulation in matrigel plugs implanted sc in Balb-c mice. Herein, we show that the anticancer activity of AN-7 and AN-9 can be attributed in part to their antiangiogenic activities suggesting potential therapeutic benefits for prostate cancer patients.
Bibliographical noteFunding Information:
This work was supported in part by grants from: CaPCURE Israel, Israeli Cancer Association (A.R.), Ministry of Commerce and Industry and Teva Pharmaceutical Industry Ltd. (A.N. and A.R.); Fellowships from the Ministry of Absorption in Science (N.T.) and The Marcus Center for Pharmaceutical and Medicinal Chemistry at Bar Ilan University (A.N.).
- Butyric acid prodrugs
- Prostate carcinoma